Drugs

pp 1–5 | Cite as

Baloxavir: First Global Approval

AdisInsight Report

Abstract

Baloxavir marboxil (Xofluza™; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi. The drug blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. In February 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections. Phase III development is underway in the USA, EU and other countries for this indication. This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Young-A Heo is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. Nature. 2006;442(7101):448–52.CrossRefPubMedGoogle Scholar
  2. 2.
    Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses. 2017;11(3):240–6.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Shionogi & Co. Ltd. XofluxaTM (baloxavir): Japanese prescribing information 2018. http://www.pmda.go.jp/. Accessed 26 Feb 2018.
  4. 4.
    Shionogi & Co. Ltd. XofluzaTM (baloxavir marboxil) tablets 10 mg/20 mg approved for the treatment of influenza types A and B in Japan [media release]. 23 Feb 2018.Google Scholar
  5. 5.
    Shionogi & Co. Ltd. Shionogi enters into a license and collaboration agreement with Roche for its anti-flu drug, S-033188 [media release]. 29 Feb 2016.Google Scholar
  6. 6.
    Watanabe A, Hirotsu N, Ishida T, et al. Pharmacokinetic/pharmacodynamic analysis of S-033188, an influenza cap-dependent endonuclease inhibitor, from a phase 2, randomized, double-blind, placebo controlled study in otherwise healthy adults with seasonal influenza [abstract no. OS0752 and oral presentation]. In: 27th European congress of clinical microbiology and infectious diseases (ECCMID). 2017.Google Scholar
  7. 7.
    Taniguchi K, Kobayash M, Ando Y, et al. Inhibitory effect of S-033188/S-033447, a novel inhibitor of influenza virus cap-dependent endonuclease, against highly pathogenic avian influenza virus A/H5N1 [abstract no. P1974 and poster]. In: 27th European congress of clinical microbiology and infectious diseases (ECCMID). 2017.Google Scholar
  8. 8.
    Kitano M, Yamamoto A, Noshi T, et al. Synergistic antiviral activity of S-033188/S-033447, a novel inhibitor of influenza virus cap-dependent endonuclease, in combination with neuraminidase inhibitors in vitro [abstract no. 1214]. Open Forum Infect Dis. 2017;4(Suppl 1):S371.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Fukao K, Ando Y, Noshi T, et al. One-day oral dosing of S-033188, a novel inhibitor of influenza virus cap-dependent endonuclease, exhibited significant reduction of viral titre and prolonged survival in mice infected with influenza B virus [abstract no. 2175 and poster]. In: 27th European congress of clinical microbiology and infectious diseases (ECCMID). 2017.Google Scholar
  10. 10.
    Fukao K, Ando Y, Noshi T, et al. Delayed dosing of S-033188, a novel inhibitor of influenza virus cap-dependent endonuclease, exhibited significant reduction of viral titer and mortality in mice infected with influenza A virus [abstract no. 1514]. Open Forum Infect Dis. 2017;4(Suppl 1):S473.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Kawasaki A, Sato C, Ishibashi T. A phase 1 study of safety, tolerability and pharmacokinetics of oral single-dose S-033188, a novel anti-influenza agent, in healthy adult male subjects [abstract no. 2238 and poster]. Open Forum Infect Dis. 2016;3(Suppl 1):S599.Google Scholar
  12. 12.
    Portsmouth S, Kawaguchi K, Arai M, et al. Cap-dependent endonuclease inhibitor S-033188 for the treatment of influenza: results from a phase 3, randomized, double-blind, placebo- and active-controlled study in otherwise healthy adolescents and adults with seasonal influenza [abstract no. LB-2]. Open Forum Infect Dis. 2017;4(Suppl 1):S734.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Shionogi & Co. Ltd. Shionogi to present S-033188 phase 3 CAPSTONE-1 study results for treatment of influenza at IDWeek 2017 [media release]. 5 Oct 2017.Google Scholar
  14. 14.
    US National Institutes of Health. ClinicalTrials.gov [identifier NCT02949011]. 2018. https://www.clinicaltrials.gov/. Accessed 05 Mar 2018.
  15. 15.
    Japan Pharmaceutical Information Center. Clinical trials informations [identifier JapicCTI-173811]. 2018. http://www.clinicaltrials.jp/. Accessed 05 Mar 2018.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations